Artepharm Global Announces Addition to Its Management Team

VANCOUVER, BRITISH COLUMBIA, Apr 06 (MARKET WIRE) --
Artepharm Global Corp. (the "Company") (OTCBB: ARGC) is pleased to
announce that Dr. Song Jianping has joined the management team as
President, in addition, he has also accepted a position on the Company's
Board of Directors.

Mr. Jianping, MD, is a 44-year-old researcher and is a Master Instructor
of Chinese Medicine Clinical Basics, specializing in the field of febrile
disease, at the Guangzhou University of Chinese Medicine. Dr. Song
graduated from Jiangxi Medical College in 1986 and from the Guangzhou
University of Chinese Medicine in 2001. He also obtained his doctorate
that same year. From 1986 to 1988, he served as a doctor in a Chinese
medicine hospital in Huichang County, Jiangxi Province. From that point
he became an Associate Professor of Jiangxi College of Traditional
Chinese Medicine, serving in this position for 10 years. Since 1998, he
has served as Associate Professor of Institute of Tropical Medicine at
Guangzhou University of Chinese Medicine, Director of the Artemisia annua
Research Center, and Research Fellow. Dr. Song has served as the General
Manager of Artepharm Co., a private company in the People's Republic of
China, sine 2004.

Artepharm Co. is a modern pharmaceutical company involved in R&D and the
manufacturing of artemisinin-based anti-malarias and anti-viral
traditional Chinese medicines. It was jointly established by a group of
experts specializing in the research of Qinghao, commonly known as
Artemisia annua. Artepharm Global Corp. has acquired the patent and
worldwide marketing rights for Artequick(R), a natural artemisinin-based
anti-malaria drug developed by Artepharm Co. For more information go to
www.artepharmglobal.com.

Safe Harbour Statements

Except for the statements of historical fact contained herein, the
information presented in this news release constitutes "forward-looking
statements" as such term is used in applicable United States and Canadian
laws. These statements relate to analyses and other information that are
based on forecasts of future results, estimates of amounts not yet
determinable and assumptions of management. Any statements that express
or involve discussions with respect to predictions, expectations,
beliefs, plans, projections, objectives, assumptions or future events or
performance (often, but not always, using words or phrases such as
"expects" or "does not expect", "is expected", "anticipates" or "does not
anticipate", "plans, "estimates" or "intends", or stating that certain
actions, events or results "may", "could", "would", "might" or "will" be
taken, occur or be achieved) are not statements of historical fact and
should be viewed as "forward-looking statements". Such forward looking
statements involve known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or achievements
of the Company to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking
statements. Such risks and other factors include, among others, the
actual results of exploration activities, the availability of capital to
fund programs and the resulting dilution caused by the raising of capital
through the sale of shares, accidents, labour disputes and other risks of
the mining industry including, without limitation, those associated with
the environment, delays in obtaining governmental approvals, permits or
financing or in the completion of development or construction activities,
title disputes or claims limitations on insurance coverage. Although the
Company has attempted to identify important factors that could cause
actual actions, events or results to differ materially from those
described in forward-looking statements, there may be other factors that
cause actions, events or results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove to be
accurate as actual results and future events could differ materially from
those anticipated in such statements. Accordingly, readers should not
place undue reliance on forward-looking statements contained in this news
release and in any document referred to in this news release.

Forward looking statements are made based on management's beliefs,
estimates and opinions on the date the statements are made and the
Company undertakes no obligation to update forward-looking statements if
these beliefs, estimates and opinions or other circumstances should
change, except as required by applicable law. Such forward-looking
statements reflect our current views with respect to future events and
are subject to certain risks, uncertainties and assumptions, including,
the risks and uncertainties outlined in our most recent financial
statements and reports and registration statement filed with the United
States Securities and Exchange Commission (the "SEC") (available at
www.sec.gov) and with Canadian securities administrators (available at
www.sedar.com). Such risks and uncertainties may include, but are not
limited to, the risks and uncertainties set forth in the Company's
filings with the SEC, such as the ability to obtain additional financing,
the effect of economic and business conditions, the ability to attract
and retain skilled personnel and factors outside the control of the
Company. These forward-looking statements are made as of the date of this
news release, and the Company assumes no obligation to update the
forward-looking statements or to update the reasons why actual results
could differ from those projected in the forward-looking statements,
except as required by applicable law. Although the Company believes that
the beliefs, plans, expectations and intentions contained in this news
release are reasonable, there can be no assurance those beliefs, plans,
expectations or intentions will prove to be accurate. Investors should
consider all of the information set forth herein and should also refer to
the risk factors disclosed in the Company's periodic reports filed from
time-to-time with the SEC. This news release shall not constitute an
offer to sell or the solicitation of an offer to buy securities of the
Company nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any
such jurisdiction.

Contacts:
Artepharm Global Corp.
(604) 575-3552
www.artepharmglobal.com

Copyright 2010, Market Wire, All rights reserved.

-0-